BeiGene | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

⟵ Back to Search Results

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Beigene Study ID

BGB-3245-AU-001

ClinicalTrials.gov ID

NCT04249843

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents